Recombinant CA 19-9 antibody

Catalog No. ABIN4949235

Product Details anti-CA 19-9 Antibody

Target: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This CA 19-9 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: Protein A affinity

Immunogen: Purified human protein used as the immunogen for the recombinant CA19-9 antibody.

Clone: CA19-9-1390R

Isotype: IgG kappa

Application Details

Application Notes: Optimal dilution of the recombinant CA19-9 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 2-4 μg/million cells in 0.1ml,Immunofluorescence: 5-10 μg/mL,Immunohistochemistry (FFPE): 5-10 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the recombinant CA19-9 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for CA 19-9

Target: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Alternative Name: CA19-9 (CA 19-9 Products)

Background: CA19-9, a carbohydrate epitope expressed on a high MW (>400  kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens.